Source: Breathe, 17 (1) 200340; 10.1183/20734735.0340-2020



Rating:

Share or cite this content

Citations should be made in the following way:
Marion Wilkens, Michael Bartlett, Frank Willersinn, Karen O'Hara, Jeanette Boyd, Jessica Denning. The patient perspective of alpha-1 antitrypsin deficiency: disease burden and unmet needs. Breathe, 17 (1) 200340; 10.1183/20734735.0340-2020

Member's Comments

No comment yet.

Related content which might interest you: The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes Source: Eur Respir J, 56 (6) 2001441; 10.1183/13993003.01441-2020 Year: 2020 Expanding the awareness of Alpha-1 antitrypsin deficiency (AATD) to provide a multidisciplinary approach to care Source: Virtual Congress 2020 – Airway diseases Year: 2020 Research priorities in alpha-1 antitrypsin deficiency (AATD) for healthcare professionals Source: Virtual Congress 2020 – COPD phenotypes Year: 2020 Alpha-1 antitrypsin deficiency and pulmonary morbidity in patients with primary immunodeficiency disease: A single center experience Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Degree of knowledge among physicians about the diagnosis and treatment of alpha-1 antitrypsin deficiency Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Trends in diagnosis and clinical presentation of alpha-1 antitrypsin deficiency within an Irish population Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 Alpha-1 antitrypsin deficiency severity and the risk of COVID-19 Source: Virtual Congress 2021 – Burden and epidemiology of COVID-19 Year: 2021 Alpha-1 antitrypsin deficiency – a potentially fatal disease Source: International Congress 2017 – Rare and common genetic variants of common and rare airway diseases Year: 2017 Decline in health status in alpha1 antitrypsin deficiency Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017 Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Diagnosis of alpha 1 antitrypsin deficiency in primary care Source: International Congress 2015 – Management of COPD and other respiratory diseases in primary care Year: 2015 Addressing unmet needs in the treatment of COPD Source: Eur Respir Rev 2014; 23: 333-344 Year: 2014 Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Targeted screening programmes in COPD: how to identify individuals with alpha 1-antitrypsin deficiency Source: Eur Respir Rev 2015; 24: 40-45 Year: 2015 Implementation of screening program for alpha-1 antitrypsin deficiency in Spain Source: Annual Congress 2004 - Emphysema and oxygen therapy Year: 2004 Unmet needs of asthma patients, and how these are reflected in attitudes to the disease and its treatment Source: Eur Respir J 2002; 20: Suppl. 38, 410s Year: 2002 Physician perspectives: barriers to diagnosing and treating severe AATD Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Unmet medical need in respiratory disease: what needs modelling in animals Source: Annual Congress 2007 - PG11 - Translation of animal models to human airway disease Year: 2007 Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011